Phase 1b, Multicenter, Open-Label Study of Marizomib Combined With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma

Trial Profile

Phase 1b, Multicenter, Open-Label Study of Marizomib Combined With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Marizomib (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 11 Apr 2018 Planned number of patients changed from 60 to 72.
    • 11 Apr 2018 Planned End Date changed from 31 Dec 2019 to 31 May 2020.
    • 11 Apr 2018 Planned primary completion date changed from 18 Jun 2018 to 18 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top